201 related articles for article (PubMed ID: 22523320)
1. Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling.
Sommer J; Effenberger T; Volpi E; Waetzig GH; Bernhardt M; Suthaus J; Garbers C; Rose-John S; Floss DM; Scheller J
J Biol Chem; 2012 Apr; 287(17):13743-51. PubMed ID: 22523320
[TBL] [Abstract][Full Text] [Related]
2. Forced homo- and heterodimerization of all gp130-type receptor complexes leads to constitutive ligand-independent signaling and cytokine-independent growth.
Suthaus J; Tillmann A; Lorenzen I; Bulanova E; Rose-John S; Scheller J
Mol Biol Cell; 2010 Aug; 21(15):2797-807. PubMed ID: 20554759
[TBL] [Abstract][Full Text] [Related]
3. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.
Pilati C; Amessou M; Bihl MP; Balabaud C; Nhieu JT; Paradis V; Nault JC; Izard T; Bioulac-Sage P; Couchy G; Poussin K; Zucman-Rossi J
J Exp Med; 2011 Jul; 208(7):1359-66. PubMed ID: 21690253
[TBL] [Abstract][Full Text] [Related]
4. Importance of the membrane-proximal extracellular domains for activation of the signal transducer glycoprotein 130.
Kurth I; Horsten U; Pflanz S; Timmermann A; Küster A; Dahmen H; Tacken I; Heinrich PC; Müller-Newen G
J Immunol; 2000 Jan; 164(1):273-82. PubMed ID: 10605021
[TBL] [Abstract][Full Text] [Related]
5. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.
Rebouissou S; Amessou M; Couchy G; Poussin K; Imbeaud S; Pilati C; Izard T; Balabaud C; Bioulac-Sage P; Zucman-Rossi J
Nature; 2009 Jan; 457(7226):200-4. PubMed ID: 19020503
[TBL] [Abstract][Full Text] [Related]
6. Combined deletion of the fibronectin-type III domains and the stalk region results in ligand-independent, constitutive activation of the Interleukin 6 signal-transducing receptor gp130.
Lamertz L; Floss DM; Scheller J
Cytokine; 2018 Oct; 110():428-434. PubMed ID: 29789201
[TBL] [Abstract][Full Text] [Related]
7. Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells.
Stuhlmann-Laeisz C; Lang S; Chalaris A; Krzysztof P; Enge S; Eichler J; Klingmüller U; Samuel M; Ernst M; Rose-John S; Scheller J
Mol Biol Cell; 2006 Jul; 17(7):2986-95. PubMed ID: 16624864
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies.
Wijdenes J; Heinrich PC; Müller-Newen G; Roche C; Gu ZJ; Clément C; Klein B
Eur J Immunol; 1995 Dec; 25(12):3474-81. PubMed ID: 8566040
[TBL] [Abstract][Full Text] [Related]
9. Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes.
Kurth I; Horsten U; Pflanz S; Dahmen H; Küster A; Grötzinger J; Heinrich PC; Müller-Newen G
J Immunol; 1999 Feb; 162(3):1480-7. PubMed ID: 9973404
[TBL] [Abstract][Full Text] [Related]
10. Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor.
Liautard J; Sun RX; Cotte N; Gaillard JP; Mani JC; Klein B; Brochier J
Cytokine; 1997 Apr; 9(4):233-41. PubMed ID: 9112331
[TBL] [Abstract][Full Text] [Related]
11. The Human GP130 Cytokine Receptor and Its Expression-an Atlas and Functional Taxonomy of Genetic Variants.
Chen YH; van Zon S; Adams A; Schmidt-Arras D; Laurence ADJ; Uhlig HH
J Clin Immunol; 2023 Dec; 44(1):30. PubMed ID: 38133879
[TBL] [Abstract][Full Text] [Related]
12. A designer hyper interleukin 11 (H11) is a biologically active cytokine.
Dams-Kozlowska H; Gryska K; Kwiatkowska-Borowczyk E; Izycki D; Rose-John S; Mackiewicz A
BMC Biotechnol; 2012 Mar; 12():8. PubMed ID: 22433466
[TBL] [Abstract][Full Text] [Related]
13. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic deletion mutants of gp130 signal from intracellular compartments.
Schmidt-Arras D; Müller M; Stevanovic M; Horn S; Schütt A; Bergmann J; Wilkens R; Lickert A; Rose-John S
J Cell Sci; 2014 Jan; 127(Pt 2):341-53. PubMed ID: 24213527
[TBL] [Abstract][Full Text] [Related]
15. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses.
Lamertz L; Rummel F; Polz R; Baran P; Hansen S; Waetzig GH; Moll JM; Floss DM; Scheller J
Sci Signal; 2018 Oct; 11(550):. PubMed ID: 30279168
[TBL] [Abstract][Full Text] [Related]
16. Two different epitopes of the signal transducer gp130 sequentially cooperate on IL-6-induced receptor activation.
Pflanz S; Kurth I; Grötzinger J; Heinrich PC; Müller-Newen G
J Immunol; 2000 Dec; 165(12):7042-9. PubMed ID: 11120832
[TBL] [Abstract][Full Text] [Related]
17. The immunoglobulin-like module of gp130 is required for signaling by interleukin-6, but not by leukemia inhibitory factor.
Hammacher A; Richardson RT; Layton JE; Smith DK; Angus LJ; Hilton DJ; Nicola NA; Wijdenes J; Simpson RJ
J Biol Chem; 1998 Aug; 273(35):22701-7. PubMed ID: 9712900
[TBL] [Abstract][Full Text] [Related]
18. TRAF2 and TRAF5 associated with the signal transducing receptor gp130 limit IL-6-driven transphosphorylation of JAK1 through the inhibition of proximal JAK-JAK interaction.
Kimura M; Nagashima H; Okuyama Y; Ishii N; So T
Int Immunol; 2018 Jun; 30(7):291-299. PubMed ID: 29668931
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma.
Poussin K; Pilati C; Couchy G; Calderaro J; Bioulac-Sage P; Bacq Y; Paradis V; Leteurtre E; Sturm N; Ramos J; Guettier C; Bardier-Dupas A; Boulai A; Wendum D; Selves J; Izard T; Nault JC; Zucman-Rossi J
Oncoimmunology; 2013 Dec; 2(12):e27090. PubMed ID: 24501689
[TBL] [Abstract][Full Text] [Related]
20. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.
Tenhumberg S; Waetzig GH; Chalaris A; Rabe B; Seegert D; Scheller J; Rose-John S; Grötzinger J
J Biol Chem; 2008 Oct; 283(40):27200-7. PubMed ID: 18650419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
